BNT221: A First-in-Human Trial With a Personalised, Autologous Neoantigen-Specific T Cell Therapy in Metastatic Melanoma
Time: 5:15 pm
day: Day One
Details:
- Understanding BNT221 Mechanism and Study Design – A personalized, neoantigenspecific autologous T cell therapy tested in a dose-finding study for advanced melanoma refractory to immune checkpoint blockade and BRAF-targeted therapy
- Navigating Safety and Tolerability – Well tolerated across doses with no severe toxicities; no cytokine release syndrome or neurotoxicity observed. Optimal dose range identified for further studies
- Evaluating Clinical and Immune Response – Six patients achieved stable disease, with some tumor reduction; strong neoantigen-specific CD4+/CD8+ T cell responses detected in blood and tumor
